Wanjia Group Holdings (401) reported revenue of approximately HK$85.706 million for the six months ended 30 September 2025, a 2.40% increase from about HK$83.695 million in the same period of 2024. Loss attributable to owners of the company was around HK$0.712 million, compared to a profit of roughly HK$1.256 million in the previous period.

Management attributed the slight revenue rise primarily to the hemodialysis segment, which saw revenue of about HK$60.089 million, reflecting a 6.42% increase. The pharmaceutical wholesale and distribution segment recorded revenue of approximately HK$25.617 million, representing a 5.93% decrease. The reduced performance of the wholesale segment was linked to lower demand for certain medical supplies.

Gross profit margin for the period was roughly 30.07%, down from 31.58% a year earlier. Selling and distribution expenses rose to HK$15.793 million, mostly attributed to larger marketing and logistics costs. Administrative expenses were HK$9.186 million, noted as a slight increase. Finance costs dropped to HK$0.613 million, partly due to lower bank loans.

As of 30 September 2025, cash and cash equivalents were HK$18.918 million, compared to HK$24.083 million at the end of March 2025. The company’s current ratio stood at around 1.96. No interim dividend was proposed.

The group reaffirmed its commitment to developing its hemodialysis treatment and consultancy business in the PRC, citing ongoing demand for such healthcare services. Management reported no material acquisitions or disposals during the reporting period and indicated that it continues to explore ways to broaden its operating scale in the medical sector.